Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
New England Journal of Medicine · 22.08.2024 · 391 (8) · 710-721
DOI: 10.1056/nejmoa2313906 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 22.08.2024. Verfasst von Toni K Choueiri und 33 weiteren Autor:innen. Beteiligte Einrichtung: From Dana-Farber Cancer Institute, Boston (T.K.C.); Barts Cancer Centre, Queen Mary University of London BRC, Royal Free NHS Trust, London (T.P.), an…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Renal Cell, Everolimus, Kidney Neoplasms. Die Arbeit wurde bisher 221-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Merck.
Abstract (Originalsprache)
BACKGROUND: Belzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in clear-cell renal-cell carcinoma in early-phase studies. METHODS: In a phase 3, multicenter, open-label, active-controlled trial, we enrolled participants with advanced clear-cell renal-cell carcinoma who had previously received immune checkpoint and antiangiogenic therapies and randomly assigned them, in a 1:1 ratio, to receive 120 mg of belzutifan or 10 mg of everolimus orally once daily until disease progression or unacceptable toxic effects occurred. The dual primary end points were progression-free survival and overall survival. The key secondary end point was the occurrence of an objective response (a confirmed complete or partial response). RESULTS: A total of 374 participants were assigned to belzutifan, and 372 to everolimus. At the first interim analysis (median follow-up, 18.4 months), the median progression-free survival was 5.6 months in both groups; at 18 months, 24.0% of the participants in the belzutifan group and 8.3% in the everolimus group were alive and free of progression (two-sided P = 0.002, which met the prespecified significance criterion). A confirmed objective response occurred in 21.9% of the participants (95% confidence interval [CI], 17.8 to 26.5) in the belzutifan group and in 3.5% (95% CI, 1.9 to 5.9) in the everolimus group (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From Dana-Farber Cancer Institute, Boston (T.K.C.); Barts Cancer Centre, Queen Mary University of London BRC, Royal Free NHS Trust, London (T.P.), and Beatson West of Scotland Cancer Centre and the University of Glasgow…
Förderung
- Merck
Zitieren
APA
Choueiri, T. K., Powles, T., Peltola, K., de Velasco, G., Burotto, M., Suarez, C., Ghatalia, P., Iacovelli, R., Lam, E. T., Verzoni, E., Gümüş, M., Stadler, W. M., Kollmannsberger, C., Melichar, B., Venugopal, B., Gross-Goupil, M., Poprach, A., De Santis, M., Schutz, F. A., …, & LITESPARK-005 Investigators (2024). Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 391(8), 710-721. https://doi.org/10.1056/nejmoa2313906
Vancouver
Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, et al. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. New England Journal of Medicine. 2024;391(8):710-721. doi:10.1056/nejmoa2313906
BibTeX
@article{Choueiri2024,
author = {Choueiri, Toni K and Powles, Thomas and Peltola, Katriina and de Velasco, Guillermo and Burotto, Mauricio and Suarez, Cristina and Ghatalia, Pooja and Iacovelli, Roberto and Lam, Elaine T and Verzoni, Elena and Gümüş, Mahmut and Stadler, Walter M and Kollmannsberger, Christian and Melichar, Bohuslav and Venugopal, Balaji and Gross-Goupil, Marine and Poprach, Alexandr and De Santis, Maria and Schutz, Fabio A and Park, Se Hoon and Nosov, Dmitry A and Porta, Camillo and Lee, Jae Lyun and Garcia-Del-Muro, Xavier and Biscaldi, Elisa and Manneh Kopp, Ray and Oya, Mototsugu and He, Li and Wang, Aobo and Perini, Rodolfo F and Vickery, Donna and Albiges, Laurence and Rini, Brian and LITESPARK-005 Investigators, LITESPARK-005 Investigators},
title = {Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma},
journal = {New England Journal of Medicine},
year = {2024},
volume = {391},
number = {8},
pages = {710--721},
doi = {10.1056/nejmoa2313906}
}
EUVIMED